(Q34657679)

3 August 2017

1 reference

title

Reporting of acute urinary retention in BPH treatment trials: importance of patient follow-up after discontinuation and case definitions (English)

1 reference

3 August 2017

1

Claus G Roehrborn

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 June 2002

1 reference

3 August 2017

1 reference

3 August 2017

volume

59

1 reference

3 August 2017

issue

6

1 reference

3 August 2017

page(s)

811-815

1 reference

Natural history of prostatism: risk factors for acute urinary retention

3 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Urinary retention in patients with BPH treated with finasteride or placebo over 4 years. Characterization of patients and ultimate outcomes. The PLESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

Long-term effects of finasteride in patients with benign prostatic hyperplasia: a double-blind, placebo-controlled, multicenter study. PROWESS Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

The Hytrin Community Assessment Trial study: a one-year study of terazosin versus placebo in the treatment of men with symptomatic benign prostatic hyperplasia. HYCAT Investigator Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2802%2901649-7

7 January 2021

10.1016/S0090-4295(02)01649-7

Identifiers

DOI

1 reference

3 August 2017

1 reference